Barclays analyst Gena Wang says Pfizer’s (PFE) Phase 3 CIFFREO study missing the primary and key secondary endpoints leaves Sarepta Therapeutics (SRPT) as the leading player in Duchenne muscular dystrophy gene therapy and highlights the importance of Elevidys’ nominal statistical significant benefit on time-to-rise and 10-meter walk/run. The firm says Pfizer’s outright failure remains an overhang for Sarepta shares. It keeps an Overweight rating on Sarepta with a $185 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta Therapeutics Expands Incentive Plan, Shareholders Vote
- Sarepta to replace ShockWave Medical in S&P 400 at open on 6/3
- Biotech Alert: Searches spiking for these stocks today
- Wynn Resorts upgraded, PayPal initiated: Wall Street’s top analyst calls
- Sarepta initiated with an Overweight at Piper Sandler